Aaron Wealth Advisors LLC Has $1.08 Million Stock Holdings in 10x Genomics $TXG

Aaron Wealth Advisors LLC raised its holdings in 10x Genomics (NASDAQ:TXG) by 68.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 66,414 shares of the company’s stock after acquiring an additional 26,884 shares during the quarter. Aaron Wealth Advisors LLC owned about 0.05% of 10x Genomics worth $1,083,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. True Wealth Design LLC increased its holdings in shares of 10x Genomics by 26.4% during the 3rd quarter. True Wealth Design LLC now owns 4,534 shares of the company’s stock valued at $53,000 after acquiring an additional 948 shares during the last quarter. Abich Financial Wealth Management LLC acquired a new position in shares of 10x Genomics during the 3rd quarter valued at about $56,000. EverSource Wealth Advisors LLC increased its holdings in shares of 10x Genomics by 203.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 7,490 shares of the company’s stock valued at $87,000 after acquiring an additional 5,025 shares during the last quarter. Focus Partners Wealth acquired a new position in shares of 10x Genomics during the 1st quarter valued at about $92,000. Finally, Earned Wealth Advisors LLC acquired a new position in shares of 10x Genomics during the 3rd quarter valued at about $118,000. 84.68% of the stock is currently owned by institutional investors and hedge funds.

10x Genomics Trading Down 0.3%

Shares of 10x Genomics stock opened at $21.82 on Wednesday. The company’s fifty day simple moving average is $19.93 and its 200-day simple moving average is $17.40. The company has a market cap of $2.79 billion, a price-to-earnings ratio of -62.34 and a beta of 2.17. 10x Genomics has a 1 year low of $6.94 and a 1 year high of $23.56.

10x Genomics (NASDAQ:TXG) last posted its quarterly earnings results on Thursday, February 12th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.06. The firm had revenue of $166.03 million during the quarter, compared to analysts’ expectations of $160.35 million. 10x Genomics had a negative return on equity of 6.89% and a negative net margin of 6.77%.The company’s revenue for the quarter was up .6% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.40) EPS. As a group, research analysts forecast that 10x Genomics will post -1.43 earnings per share for the current fiscal year.

Insider Buying and Selling at 10x Genomics

In other 10x Genomics news, insider Benjamin J. Hindson sold 7,826 shares of the company’s stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $18.58, for a total value of $145,407.08. Following the completion of the transaction, the insider owned 424,779 shares of the company’s stock, valued at $7,892,393.82. This represents a 1.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Adam Taich sold 8,968 shares of the company’s stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $18.58, for a total value of $166,625.44. Following the completion of the transaction, the chief financial officer directly owned 288,417 shares of the company’s stock, valued at approximately $5,358,787.86. This trade represents a 3.02% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 41,426 shares of company stock valued at $779,895 in the last quarter. Corporate insiders own 9.39% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Leerink Partners lowered their price objective on 10x Genomics from $22.00 to $20.00 and set a “market perform” rating on the stock in a report on Tuesday, January 27th. William Blair raised 10x Genomics from a “market perform” rating to an “outperform” rating in a report on Tuesday, March 31st. Bank of America set a $21.00 price objective on 10x Genomics in a report on Monday, January 12th. Barclays increased their price objective on 10x Genomics from $17.00 to $22.00 and gave the company an “overweight” rating in a report on Monday, December 15th. Finally, Citigroup boosted their target price on shares of 10x Genomics from $18.00 to $24.00 and gave the stock a “neutral” rating in a research report on Tuesday. Five investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $18.89.

10x Genomics Company Profile

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.